At what prices did the TXG CEO’s June 22, 2026 share sales occur?

The reported sales used weighted average prices around $33–$36 per share. Footnotes state they were executed in multiple trades within ranges from $32.75 up to $36.24, with each line’s figure representing a weighted average sale price.

What indirect TXG share holdings are associated with trusts for Serge Saxonov?

The filing lists 71,644 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants’ Trust, and 27 shares in the Y/S Pot Trust. The footnotes note that Serge Saxonov serves as trustee for each of these trusts.

10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported open-market sales of 30,000 shares of Class A common stock on June 22, 2026. The sales occurred in multiple trades at weighted average prices around $33–$36 per share, as detailed by price ranges in the filing.

The transactions were made under Saxonov’s pre-arranged Rule 10b5-1 trading plan, adopted on November 29, 2025. After these sales, he holds approximately 1,129,853 shares directly, plus additional indirect holdings through the Andromeda Trust, the Y/S Descendants’ Trust, and the Y/S Pot Trust.

Insider Trade Summary 10b5-1

Net Seller: 30,000 shares ($1,033,269)

Net Sell 7 txns

Insider Saxonov Serge

Role Chief Executive Officer

Sold 30,000 shs ($1.03M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	8,527	$33.289	$284K
Sale	Class A Common Stock	9,991	$34.2815	$343K
Sale	Class A Common Stock	9,821	$35.3159	$347K
Sale	Class A Common Stock	1,661	$36.1646	$60K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,129,853 shares (Direct, null); Class A Common Stock — 27 shares (Indirect, See footnote)

Footnotes (1)

The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. This transaction was executed in multiple trades at prices ranging from $32.75 to $33.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $33.76 to $34.71, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $34.86 to $35.82, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $35.98 to $36.24, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

Key Figures

Shares sold: 30,000 shares Sale price (weighted average example): $33.2890 per share Sale price (weighted average example): $36.1646 per share +4 more

7 metrics

Shares sold 30,000 shares Total net sales of Class A common stock on June 22, 2026

Sale price (weighted average example) $33.2890 per share One reported weighted average sale price range $32.75–$33.74

Sale price (weighted average example) $36.1646 per share One reported weighted average sale price range $35.98–$36.24

Direct holdings after transactions 1,129,853 shares Class A common stock held directly by Serge Saxonov after June 22, 2026 sales

Andromeda Trust holdings 71,644 shares Class A common stock held indirectly via Andromeda Trust

Y/S Descendants’ Trust holdings 213,250 shares Class A common stock held indirectly via Y/S Descendants’ Trust

Y/S Pot Trust holdings 27 shares Class A common stock held indirectly via Y/S Pot Trust

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, open-market sale, Andromeda Trust, +2 more

6 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Andromeda Trust financial

"The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee."

Y/S Descendants' Trust financial

"The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee."

Y/S Pot Trust financial

"The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 01:23 PM Accepted by SEC EDGAR 06/24/2026 - 01:22 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last)

(First)

(Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON

CALIFORNIA

94588

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/22/2026		S⁽¹⁾		8,527	D	$33.289⁽²⁾	1,129,853	D
Class A Common Stock	06/22/2026		S⁽¹⁾		9,991	D	$34.2815⁽³⁾	1,119,862	D
Class A Common Stock	06/22/2026		S⁽¹⁾		9,821	D	$35.3159⁽⁴⁾	1,110,041	D
Class A Common Stock	06/22/2026		S⁽¹⁾		1,661	D	$36.1646⁽⁵⁾	1,108,380	D
Class A Common Stock								27	I	See footnote⁽⁶⁾
Class A Common Stock								213,250	I	See footnote⁽⁷⁾
Class A Common Stock								71,644	I	See footnote⁽⁸⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $32.75 to $33.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $33.76 to $34.71, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $34.86 to $35.82, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $35.98 to $36.24, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

6. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

7. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

8. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did 10x Genomics (TXG) CEO Serge Saxonov report?

Serge Saxonov reported selling 30,000 shares of 10x Genomics Class A common stock in open-market transactions on June 22, 2026. These trades were executed in multiple lots at several price ranges disclosed in the filing.

Was the 10x Genomics (TXG) CEO’s stock sale under a Rule 10b5-1 plan?

Yes. A footnote explains the transactions were effected pursuant to Serge Saxonov’s Rule 10b5-1 trading plan adopted on November 29, 2025. Such pre-arranged plans schedule trades in advance, making the timing more routine.

How many TXG shares does CEO Serge Saxonov hold after the reported sales?

Following the June 22, 2026 transactions, the filing shows Serge Saxonov holding about 1,129,853 shares of Class A common stock directly. He also has indirect holdings through several trusts identified in the footnotes.

How many TXG shares did the CEO sell in total on June 22, 2026?

The transaction summary shows total net sales of 30,000 shares of 10x Genomics Class A common stock. This figure aggregates four separate open-market sale entries reported for that date in the non-derivative transaction table.